Anthony Johnson
Empire Genomics LLC, USA
Title: Developing a companion Dx in oncology: From academic research project to companion trial
Biography
Biography: Anthony Johnson
Abstract
This talk will explore the complexities and timelines of licensing a novel genomic technology from Emory University and developing the assay into a companion Dx with a major pharmaceutical partner (Takeda Millennium). We will discuss the process, the key stakeholders as well as key issues that need to be considered and managed in order to ultimately end up with a marketable test in the end. The talk will center on the Empire Genomic Companion Dx assay for proteasome inhibitors in the disease multiple myeloma and the active companion trial NCT02765854. In order to proceed from the bench to the bedside, diagnostic technologies must demonstrate robust scientific data, health economic benefits and the ability to ultimately help clinicians make disease management decisions based on testing results.
